Novel chimeric histone deacetylase inhibitors: A series of lapatinib hybrides as potent inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and histone deacetylase activity

Journal of Medicinal Chemistry

Volumn 53, Issue 24, 2010, Pages 8546-8555

  Mahboobi, Siavosh ^a   Sellmer, Andreas ^a   Winkler, Matthias ^a   Eichhorn, Emerich ^a   Pongratz, Herwig ^a   Ciossek, Thomas ^b   Baer, Thomas ^b   Maier, Thomas ^b   Beckers, Thomas ^c  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b Nycomed GmbH   (Germany)

^c CHARLES RIVER LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACRYLAMIDE DERIVATIVE; BETA ACTIN; CELL DIVISION KINASE 2; CYCLIC AMP DEPENDENT PROTEIN KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HISTONE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HISTONE H3; INSULIN RECEPTOR; LAPATINIB; LYSINE; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; POLO LIKE KINASE 1; POLYCYCLIC AROMATIC HYDROCARBON DERIVATIVE; UNCLASSIFIED DRUG;

ACETYLATION; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER RESISTANCE; CHIMERA; CHROMATIN STRUCTURE; CONTROLLED STUDY; CUTANEOUS T CELL LYMPHOMA; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG SELECTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; STRUCTURE ACTIVITY RELATION;

ACETYLATION; ACRYLAMIDES; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; HISTONE DEACETYLASE INHIBITORS; HISTONES; HUMANS; ISOENZYMES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 78650321835     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm100665z     Document Type: Article

References (26)

1. Lin, H.-Y.; Chen, C.-S.; Lin, S.-P.; Weng, J.-R.; Chen, C.-S. Targeting Histone Deacetylase in Cancer Therapy Med. Res. Rev. 2006, 26 (4) 397-413
2. Minucci, S.; Pelicci, P. G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer Nat. Rev. Cancer 2006, 6 (1) 38-51
3. Jiahuai, T.; Cang, S.; Ma, Y.; Petrillo, R. L.; Liu, D. Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents J. Hematol. Onco.l 2010, 3, 5
4. Prince, H. M.; Bishton, M. J.; Harrison, S. J. Clinical Studies of Histone Deacetylase Inhibitors Clin. Cancer Res. 2009, 15 (12) 3958-3969
5. Bots, M.; Johnstone, R. W. Rational Combinations Using HDAC Inhibitors Clin. Cancer Res. 2009, 15 (12) 3970-3977
6. Mercurio, C.; Minucci, S.; Pelicci, P. G. Histone deacetylases and epigenetic therapies of hematological malignancies Pharm. Res. 2010, 62 (1) 18-34
7. Morgan, M. A.; Reuter, C. W. Molecularly targeted therapies in myelodysplastic syndromes and acute myeloid leukemias Ann. Hematol. 2006, 85 (3) 139-163
8. Johnstone, R. W.; Licht, J. D. Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell 2003, 4 (1) 13-18
9. Sorbera, L. A. Epigenetic target as an approach to cancer therapy and chemoprevention Drugs Future 2006, 31 (4) 335-344
10. Ma, B. B. Y.; Sung, F.; Tao, Q.; Poon, F. F.; Lui, V. W.; Yeo, W.; Chan, S. L.; Chan, A. T. C. The preclinical activity of the histone deacetylase inhibitor PXD101 (belinostat) in hepatocellular carcinoma cell lines Investigational New Drugs 2010, 28 (2) 107-114
11. Buggy, J. J.; Cao, Z. A.; Bass, K. E.; Verner, E.; Balasubramanian, S.; Liu, L.; Schultz, B. E.; Young, P. R.; Dalrymple, S. A. CRA-024781: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivo Mol Cancer Ther. 2006, 5 (5) 1309-1317
12. Atadja, P. W. Use of HDAC inhibitors for the treatment of acute myeloid leukemia and/or myelodysplastic syndrome. PCT Int. Appl. (2010) WO 2010009285 A1.
13. Geyer, C.; Forster, J.; Lindquist, D.; Chan, S.; Romieu, C.; Pienkowski, T.; Jagiello-Gruszfeld, A.; Crown, J.; Chan, A.; Kaufman, B.; Skarlos, D.; Campone, M.; Davidson, N.; Berger, M.; Oliva, C.; Rubin, S.; Stein, S.; Cameron, D. Lapatinib plus capecitabine for HER2-positive advanced breast cancer N. Engl. J. Med. 2006, 355 (26) 2733-2743
14. Nishino, S.; Hirotsu, K.; Shima, H.; Harada, T.; Oda, H.; Takahashi, T.; Suzuki, S. Process for producing 3,4-dihydroquinazolin-4-one derivatives. PCT Int. Appl. WO2003064399 A1, 2003.
15. Nishino, S.; Hirotsu, K.; Shima, H.; Harada, T.; Oda, H. Process for producing 4-aminoquinazoline compound by chlorination of quinazolin-4-one or its derivative and amination. PCT Int. Appl. WO 2003066602, 2003.
16. Wallace, E.; Topolov, G.; Zhao, Q.; Lyssikatos, J. P. Preparation of cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors. US 2005101617, 2005.
17. 2+ Release from Sarcoplasmic Rerticulum of Mouse Skeletal Muscle Bioorg. Med. Chem. 2003, 11, 663-673
18. Zhang, J.; Xiong, C.; Ying, J.; Wang, W.; Hruby, V. J. Stereoselective Synthesis of Novel Dipeptide β-Turn Mimetics Targeting Melanocortin Peptide Receptors Org. Lett. 2003, 5 (17) 3115-3118
19. Castro, B.; Dormoy, J. R.; Evin, G.; Selve, C. Peptide coupling reagents. IV. N-[Oxytris(dimethylamino)phosphonium]benzotriazole hexafluorophosphate Tetrahedron Lett. 1975, 14, 1219-1222
20. Petasis, N. A.; Patel, Z. D. Synthesis of piperazinones and benzopiperazinones from 1,2-diamines and organoboronic acids Tetrahedron Lett. 2000, 41, 9607-9611
21. Mahboobi, S.; Sellmer, A.; Winkler, M.; Eichhorn, E.; Pongratz, H.; Ciossek, T.; Baer, T.; T., M.; Beckers, T. Novel designed chimeric HDAC- and tyrosine kinase inhibitors: A series of Imatinib hybrides as potent inhibitors of wild-type and mutant BCR-ABL, PDGF-Rβ and histone deacetylases J. Med. Chem. 2009, 52 (8) 2265-2279
22. Beckers, T.; Burkhardt, C.; Wieland, H.; Gimmnich, P.; Ciossek, T.; Maier, T.; Sanders, K. Distinct pharmacological properties of 2nd generation HDAC inhibitors with the benzamide or hydroxamate head group Int. J. Cancer 2007, 121, 1138-1148
23. Wegener, D.; Wirsching, F.; Riester, D.; Schwienhorst, A. A fluorogenic histone deacetylase assay well suited for high-throughput activity screening Chem. Biol. 2003, 10 (1) 61-68
24. Braunger, J.; Zoche, M.; Schmidt; Wiesbacher, M.; Burkhardt, C.; Gekeler, V.; Beckers, T. AACR Annual Conference 2003, Abstract 4556.
25. O'Brian, J.; Wilson, I.; Orton, T.; Pognan, F. Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell toxicity Eur. J. Biochem. 2000, 267 (17) 5421-5426
26. Roschangar, F.; Brown, J. C.; Cooley, B. E.; Sharp, M. J.; Matsuoka, R. T. Use of lithium N,O-dimethylhydroxylamide as an efficient in situ protecting agent for aromatic aldehydes Tetrahedron 2002, 58 (9) 1657-1666